Innovate Biopharmaceuticals Announces Acceptance of Two Abstracts for the Digestive Disease Week 2018 Conference
May 09 2018 - 2:07PM
Highlighting the Dose Response and
Mechanism of Action of Larazotide Acetate
Innovate Biopharmaceuticals, Inc. (Nasdaq:INNT), a clinical stage
biotechnology company focused on developing novel therapeutics for
autoimmune and inflammatory diseases, announced that two abstracts
were accepted for poster presentations during the 2018 Digestive
Disease Week (DDW) conference being held June 2-5, 2018 in
Washington, DC. These abstracts, jointly authored with NC
State University, showcase larazotide acetate’s ability to
stimulate the recovery of ischemic-injured intestinal tissue by
regulating tight junctions.
Date/Time: Saturday, June 2 from 12:00pm – 2:00pm ETTitle:
Larazotide Stimulates Recovery of Ischemic-Injured Intestine in a
Dose-Dependent Manner Associated with Restoration of Tight
JunctionsSession Number: 5050Presentation Number: Sa 1183Room: Hall
C
Date/Time: Sunday, June 3 from 12:00pm – 2:00pm ETTitle:
Larazotide Stimulates Recovery of Ischemic-Injured Intestine in The
Presence of the Non-Steroidal Anti-Inflammatory Drug (NSAID)
Indomethacin Related to Recovery of Tight JunctionsSession Number:
6285Presentation Number: Su 2039Room: Hall C
Christopher Prior, Ph.D., CEO of Innovate, said, “It is
remarkable that larazotide acetate has been shown to restore
structural integrity of an intestinal wall following such a severe
ischemic insult and is yet another demonstration of how this
oral peptide has the potential to reduce permeability of the
gut. We believe this broad mechanism offers great promise at
preventing undesirable antigens in the lumen of the intestine from
entering the body and triggering inflammation leading to tissue
damage and dysfunction of critical organs. We are excited to
explore this mode of action in the treatment of celiac disease, our
lead program, and in liver diseases such as NASH.”
“I have not seen a compound work so effectively in this model.
We demonstrated a narrow range low dose response that would
approximate active dose levels in humans. We are continuing to
demonstrate the broad range of antigens that are prevented from
crossing the intestinal wall following treatment with larazotide,”
remarked Anthony Blikslager, DVM, PhD, DACVS, AGAF, Professor of
Equine Surgery and Gastroenterology at NC State University’s
College of Veterinary Medicine.
About Innovate Biopharmaceuticals, Inc. (Nasdaq:
INNT): Innovate is a clinical stage biotechnology company
focused on developing novel therapeutics for autoimmune and
inflammatory diseases. Innovate’s lead drug candidate, larazotide
acetate, has a mechanism of action that renormalizes the
dysfunctional intestinal barrier by decreasing intestinal
permeability and reducing antigen trafficking, such as gliadin
fragments in celiac disease, and bacterial toxins and immunogenic
antigens in nonalcoholic steatohepatitis (NASH). In several
diseases, including celiac disease, NASH, Crohn’s disease,
ulcerative colitis, irritable bowel syndrome (IBS), type 1 diabetes
mellitus (T1DM), chronic kidney disease (CKD), the intestinal
barrier is dysfunctional with increased permeability.
In celiac disease, larazotide is the only drug which has
successfully met the primary endpoint with statistical significance
in a Phase 2b efficacy clinical trial (342-patients). Innovate
successfully completed the End of Phase 2 Meeting with the FDA in
2017 and is preparing for larazotide to begin Phase 3 registration
clinical trials for celiac disease later in 2018. Larazotide has
been exposed to more than 500 subjects in clinical trials
demonstrating a favorable safety profile comparable to placebo for
long-term chronic administration. Larazotide has received Fast
Track designation from the FDA for celiac disease.
Forward Looking Statements This press release
includes forward-looking statements including, but not limited to,
statements related to the potential for Innovate’s drug development
pipeline candidates in treating the diseases and conditions for
which they are being developed, Innovate’s start of clinical trials
for celiac disease, NASH, Crohn’s disease, and ulcerative colitis,
and Innovate’s ability to develop future collaborations. The
forward-looking statements contained in this press release are
based on management’s current expectations and are subject to
substantial risks, uncertainty and changes in circumstances. Actual
results may differ materially from those expressed by these
expectations due to risks and uncertainties, including, among
others, those related to our ability to obtain additional capital
on favorable terms to us, or at all, the success, timing and cost
of our drug development program and our ongoing or future clinical
trials, the lengthy and unpredictable nature of the drug approval
process, and our ability to commercialize our product candidates if
approved. These risks and uncertainties include, but may not be
limited to, those described in our Annual Report on Form 10-K filed
with the U.S. Securities and Exchange Commission (the “SEC”) on
March 14, 2018, and in any subsequent filings with the SEC.
Forward-looking statements speak only as of the date of this press
release, and we undertake no obligation to review or update any
forward-looking statement except as may be required by applicable
law.
Innovate Biopharmaceuticals, Inc.Kendyle
WoodardTel: 919-275-1933Email:
investor.relations@innovatebiopharma.com
www.innovatebiopharma.com
Innovate Biopharmaceutic... (NASDAQ:INNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Innovate Biopharmaceutic... (NASDAQ:INNT)
Historical Stock Chart
From Apr 2023 to Apr 2024